title: [Main therapeutic advances in IBD in 2007].
abstract: In 2008 three biological agents against TNFalpha will be available. The combination of infliximab with azathioprine is no longer recommended, as hepatosplenic lymphomas with a particularly bad prognosis have been associated with this combined therapy. Regular maintenance therapy with infliximab is as effective in preventing the development of anti-infliximab antibodies as co-administration of this anti-TNFalpha agent with an immunomodulator. The benefit of regular maintenance therapy is probably linked to the presence of residual trough levels of infliximab between perfusions.
authors.affiliation: Service de gastro-entérologie et hépatologie, CHUV, 1011 Lausanne.
authors.forename: Christian
authors.initials: C
authors.lastname: Felley
authors.forename: Christian
authors.initials: C
authors.lastname: Mottet
authors.forename: Michel H
authors.initials: MH
authors.lastname: Maillard
authors.forename: Jurg
authors.initials: J
authors.lastname: Hess
authors.forename: Joakim
authors.initials: J
authors.lastname: Delarive
authors.forename: Pierre
authors.initials: P
authors.lastname: Michetti
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068582:Certolizumab Pegol; D003093:Colitis, Ulcerative / Q000188:drug therapy; D003424:Crohn Disease / Q000188:drug therapy / Q000601:surgery; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D000069285:Infliximab; D043183:Irritable Bowel Syndrome / Q000188:drug therapy*; D011092:Polyethylene Glycols / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha; D011092:Polyethylene Glycols; D000069285:Infliximab; D000068879:Adalimumab; D000068582:Certolizumab Pegol